Abcam (ABCZF) Short-Term Debt : $148.6 Mil (As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Abcam Short-Term Debt?

Abcam's Short-Term Debt for the quarter that ended in Jun. 2023 was $148.6 Mil.

Abcam's quarterly Short-Term Debt declined from Jun. 2022 ($147.0 Mil) to Dec. 2022 ($145.7 Mil) but then increased from Dec. 2022 ($145.7 Mil) to Jun. 2023 ($148.6 Mil).

Abcam's annual Short-Term Debt increased from Jun. 2019 ($0.0 Mil) to Jun. 2020 ($133.2 Mil) and increased from Jun. 2020 ($133.2 Mil) to Dec. 2022 ($145.7 Mil).

Abcam Short-Term Debt Historical Data

The historical data trend for Abcam's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Short-Term Debt Chart

Abcam Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec22

Short-Term Debt

Get a 7-Day Free Trial

133.17

145.68

Abcam Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
Short-Term Debt	Get a 7-Day Free Trial															-	-	147.04	145.68	148.61

Abcam Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Abcam Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Abcam's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Abcam (ABCZF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.